ScoreWhy is Kabra Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 9,274.00% and Operating profit at 404.05% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0.40 times
2
With a growth in Net Sales of 16.4%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(Latest six months) Higher at Rs 65.83 cr
- PAT(Latest six months) Higher at Rs 3.63 cr
- PBT LESS OI(Q) At Rs 1.31 cr has Grown at 42.4% (vs previous 4Q average)
3
Stock is technically in a Mildly Bearish range
- The technical trend has deteriorated from Mildly Bullish on 17-Jun-26 and has generated -2.99% returns since then
- The stocks MACD and KST technical factors are also Bearish
4
With ROE of 19.1, it has a Very Attractive valuation with a 2.3 Price to Book Value
- Over the past year, while the stock has generated a return of 102.05%, its profits have risen by 555%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Kabra Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kabra Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Kabra Drugs
102.05%
1.84
55.43%
Sensex
-4.95%
-0.37
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9,274.00%
EBIT Growth (5y)
404.05%
EBIT to Interest (avg)
0.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.01
Tax Ratio
13.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-26.76%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
12
Industry P/E
34
Price to Book Value
2.25
EV to EBIT
9.00
EV to EBITDA
8.88
EV to Capital Employed
3.19
EV to Sales
0.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
35.42%
ROE (Latest)
19.08%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
NET SALES(Latest six months)
Higher at Rs 65.83 cr
PAT(Latest six months)
Higher at Rs 3.63 cr
PBT LESS OI(Q)
At Rs 1.31 cr has Grown at 42.4% (vs previous 4Q average
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Kabra Drugs
Net Sales - Latest six months
At Rs 65.83 cr has Grown at 6,582,999,900.00%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
At Rs 3.63 cr has Grown at 2,520.00%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1.31 cr has Grown at 42.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 0.92 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Net Sales - Latest six months
Higher at Rs 65.83 cr
than preceding 12 month period ended Mar 2026 of Rs 26.91 crMOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 3.63 cr
than preceding 12 month period ended Mar 2026 of Rs 1.19 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
